Key Highlights

  • NVO shares fell 8.88% today to $46.88, down from a prior close of $51.61.
  • The Phase 3 ZEUS trial for ziltivekimab failed to meet its primary endpoint, showing no reduction in major adverse cardiovascular events versus placebo (hazard ratio 0.99).
  • The trial enrolled over 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation.
  • The outcome will result in a non-cash impairment charge in the third quarter of 2026 but will not affect Novo Nordisk's previously communicated 2026 operating profit outlook.

ZEUS Trial Fails Despite Confirmed Biological Effect

Novo Nordisk A/S (NYSE:NVO) shares are sinking today after the company announced that its Phase 3 ZEUS cardiovascular outcomes trial for ziltivekimab failed to meet its primary endpoint, showing no reduction in major adverse cardiovascular events versus placebo in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. Novo Nordisk, headquartered in Bagsvaerd, Denmark and founded in 1923, is a leading global healthcare company operating through Diabetes and Obesity Care, and Rare Disease segments, with leading therapies including Ozempic and Wegovy.

While ziltivekimab demonstrated target engagement and inhibition of the IL-6 inflammatory pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive protein, this did not translate into a reduction in cardiovascular events, with a hazard ratio of 0.99 essentially indicating no benefit over placebo. The trial enrolled more than 6,300 participants and evaluated once-monthly ziltivekimab 15 mg for reducing the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke.

Financial Impact and Ongoing Pipeline

Novo Nordisk carries a market capitalization of approximately $208.97 billion, with shares trading at a trailing price-to-earnings ratio of 11.67 and a dividend yield of 3.82%. The stock's 52-week range spans $35.12 to $64.16.

The company said the ZEUS outcome will not impact its previously communicated 2026 adjusted operating profit outlook but will result in a non-cash impairment charge in the third quarter. Two additional ongoing cardiovascular outcomes trials investigating ziltivekimab, in people with heart failure and in people following an acute heart attack, are planned to continue and are anticipated to read out in the first half of 2027.

Chief Scientific Officer Martin Holst Lange said the result does not change the company's strategic commitment to cardiovascular disease, noting the study provides important scientific evidence to inform ongoing research. The setback compounds existing investor concerns about Novo Nordisk's heavy reliance on Ozempic and Wegovy sales amid intensifying GLP-1 competition from rivals including Eli Lilly (NYSE:LLY), ahead of the company's second-quarter earnings report due August 5.

Conclusion

Novo Nordisk's decline reflects a genuine clinical setback for ziltivekimab, even though the company maintains its broader cardiovascular disease commitment and says the outcome will not affect its 2026 profit guidance. With two additional ziltivekimab cardiovascular trials still pending and Q2 earnings due August 5, investors will be watching for further clarity on the company's pipeline diversification beyond its core GLP-1 franchise.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.